Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas

Journal of Occupational and Environmental Medicine

Volumn 47, Issue 12, 2005, Pages 1218-1226

  Sawyer, Richard T ^a,b,d   Abraham, Jerrold L ^c   Daniloff, Elaine ^a   Newman, Lee S ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERYLLIUM;

ADULT; AGED; ARTICLE; BERYLLIOSIS; CERAMICS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; LUNG GRANULOMA; LUNG PARENCHYMA; LYMPHOCYTE PROLIFERATION; MALE; MASS SPECTROMETRY; OCCUPATIONAL EXPOSURE; TISSUE SECTION; TRANSBRONCHIAL BIOPSY;

EID: 29144515699     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000184884.85325.36     Document Type: Article

References (36)

1. Maier LA, Newman LS. Beryllium disease. In: Rom WN, ed. Environmental and Occupational Medicine. 3rd ed. Philadelphia: Lippincott; 2000:1021-1035.
2. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Re-examination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol. 1991;191:54-60.
3. Kreiss K, Mroz MM, Zhen H, Wiedemann H, Barna B. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med. 1997;54:605-612.
4. Newman LS, Balkissoon R, Daniloff E, Solida M, Mroz M. Rate of progression from beryllium sensitization to chronic beryllium disease is 9-19% per year. Am J Respir Crit Care Med. 1998;157:A145.
5. Stange AW, Hilmas DE, Furman FJ, Gatliffe FJ. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg. 2001;16:405-417.
6. Newman LS. Beryllium disease and sarcoidosis. Clinical and laboratory links. Sarc Vasc Diffuse Lung Dis. 1995;2:7-19.
7. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224-1234.
8. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry: blood test performance and exposure-disease relations. J Occup Med. 1993;35:267-274.
9. Ferris BG. Epidemiology Standardization Project. Am Rev Respir Dis. 1978;118:1-120.
10. Newman LS, Kreiss K, King TR Jr., Saey S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease: re-examination of disease definition and natural history. Am Rev Rsipir Dis. 1989;39:1479-1486.
11. Hunninghake GW, Costabel U, Ando M, et al. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;60:736-755.
12. Watters LC, Schwartz MI, Cherniak RM. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationship with lung histopathology and clinical response to therapy. Am Rev Respir Dis. 1997;135:696-704.
13. Abraham JL, Rossi R, Marquez N. Ion microprobe mass analysis of beryllium in situ in human lung: preliminary results. In: Johari O, ed. Scanning Electron Microscopy. Chicago: I.I.T. Research Institute; 1976:501-506.
14. th International Conference on Sarcoidosis. Cardiff: Alpha Omega Pub Ltd; 1980:38-46.
15. Tukey JW. The Problem of Multiple Comparisons (dittoed manuscript of 396 pages). Princeton University; 1953.
16. Kramer CY. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics. 1956;12:309-310.
17. Freiman DG, Hardy HL. Beryllium disease: the relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. Beryllium Case Registry. Hum Pathol. 1970;1:25-44.
18. Williams WJ, Wallach ER. Laser microprobe mass spectrometry (LAMMS) analysis of beryllium, sarcoidosis and other granulomatous diseases. J Sarcoidosis. 1989;6:111-117.
19. Butnor KJ, Sporn TA, Ingram P, Gunasegaram S, Pinto JF, Roggli VL. Beryllium detection in human lung tissue using electron probe X-ray microanalysis. Mod Pathol. 2003;16:1171-1177.
20. Schepers GWH. The mineral content of the lung in chronic berylliosis. Dis Chest. 1962;42:600-607.
21. Berry JP, Escaig F, Galle P. Etude de la localization intracellularie du beryllium par microscopie innique analytique. CR Acad Sci Paris Sci Vie. 1987;304:239-243.
22. Berry JP, Mentre P, Hallegot P, Levi-Setti R, Galle P. Cytochemical study of abnormal intranuclear structures rich in beryllium. Biol Cell. 1989;67:147-157.
23. Duckett S, Kradin R, Galle P. The pathogenesis of beryllium-induced pulmonary granulomatosis. A scanning secondary ion analytical microscopy study. Comptes Rendus de l'Academe des Sciences - Serie III. 2000;323:769-774.
24. Hallegot P, Berry JP, Levi-Setti R, Chabala JM, Galle P. Metabolism of beryllium: a scanning ion microprobe analysis. Trace Elem Med. 1989;6:96-103.
25. Levi-Setti R, Berry JP, Chabala JM, Galle P. Selective intracellular beryllium localization in rat tissue by mass-resolved ion microprobe imaging. Biol Cell. 1988;63:77-82.
26. Vourlekis JS, Sawyer RT, Newman LS. Sarcoidosis: developments in etiology, immunology, and therapeutics. Adv Intern Med. 2000;5:209-257.
27. + T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA. 2000;97:12717-12722.
28. + T cells in patients with chronic beryllium disease. J Clin Invest. 2002;110:1473-1482.
29. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989;20:1103-1109.
30. + T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol. 2004;1:122-130.
31. Wang Z, White SP, Petrovic M, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999;163:1647-1653.
32. Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med. 2004;46:95-103.
33. Day GA, Hoover MD, Stefaniak AB, et al. Bioavailability of beryllium oxide particles: an in vitro study in the murine J774A. 1 macrophage cell line model. Exp Lung Res. 2005;31:341-360.
34. Sawyer RT, Maier LA, Newman LS. Chronic beryllium disease: a model interaction between innate and acquired immunity. Internatl Immunopharmacol. 2002;2:249-261.
35. Hennebereger PK, Cumro D, Dubner DD, Kent MS, McCawley M, Kreiss K. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Internatl Arch Occup Env Health. 2001;74:167-176.
36. Schuler CR, Kent MS, Deubner DC, et al. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med. 2005;47:195-205.